Literature DB >> 9189170

Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide.

D M Brizel1, W D Hage, R K Dodge, M T Munley, C A Piantadosi, M W Dewhirst.   

Abstract

This laboratory previously demonstrated that hyperbaric oxygen and hyperbaric carbogen improved oxygenation in the R3230Ac tumor, but normobaric 100% O2 and carbogen did not. The current study assessed tumor growth after exposure to radiation plus either hyperbaric oxygen, carbogen or carbogen/nicotinamide and the relationship between pretreatment tumor oxygenation and growth time. R3230Ac carcinomas were grown in the flanks of F344 rats. Animals were randomized to one of seven radiation treatment groups: sham irradiation or irradiation plus room air, hyperbaric oxygen (100% O2/3 atmospheres), nicotinamide (0.3 mg/g intraperitoneally 20 min before irradiation), carbogen, carbogen/nicotinamide or hyperbaric oxygen/nicotinamide. Tumors received 20 Gy in a single dose. Median growth times were 6, 18, 18, 20, 22, 28 and 27 days for controls and irradiation plus room air, carbogen, nicotinamide, carbogen/nicotinamide, hyperbaric oxygen and hyperbaric oxygen/nicotinamide, respectively. Irradiation with hyperbaric oxygen, hyperbaric oxygen/ nicotinamide and carbogen/nicotinamide increased growth time (P < 0.001, P < 0.001 and P = 0.003, respectively) relative to room air. Hyperbaric oxygen was significantly more effective than carbogen/nicotinamide (P = 0.001). Growth times for all tumors exposed to hyperbaric oxygen were longer than those of the most fully oxygenated tumors (no baseline pO2 values < 10 mm Hg) not exposed to hyperbaric oxygen (P < 0.001). These results suggest that hyperbaric oxygen may improve radiation response by additional mechanisms separate from overcoming the oxygen effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9189170

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

Review 1.  In Vivo Application of Proton-Electron Double-Resonance Imaging.

Authors:  Shun Kishimoto; Murali C Krishna; Valery V Khramtsov; Hideo Utsumi; David J Lurie
Journal:  Antioxid Redox Signal       Date:  2017-11-13       Impact factor: 8.401

2.  (18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings.

Authors:  Tao Huang; A Cahid Civelek; Huaiyu Zheng; Chin K Ng; Xiaoxian Duan; Junling Li; Gregory C Postel; Baozhong Shen; Xiao-Feng Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

3.  Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia.

Authors:  Oliver Thews; Peter Vaupel
Journal:  Strahlenther Onkol       Date:  2015-10-26       Impact factor: 3.621

4.  Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.

Authors:  Jennifer L H Johnson; Rafael A Leos; Amanda F Baker; Evan C Unger
Journal:  J Biomed Nanotechnol       Date:  2015-02       Impact factor: 4.099

5.  The effects of hyperoxic and hypercarbic gases on tumour blood flow.

Authors:  T J Dunn; R D Braun; W E Rhemus; G L Rosner; T W Secomb; G M Tozer; D J Chaplin; M W Dewhirst
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 6.  Targeting Hypoxia: Revival of Old Remedies.

Authors:  Nuria Vilaplana-Lopera; Maxym Besh; Eui Jung Moon
Journal:  Biomolecules       Date:  2021-10-29

7.  Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.

Authors:  Shu-Ling Zhang; Cheng-Bo Han; Li Sun; Le-Tian Huang; Jie-Tao Ma
Journal:  Radiat Oncol       Date:  2020-08-24       Impact factor: 3.481

8.  Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF‑1α and VEGF expression.

Authors:  Dan Dong; Yan Fu; Feng Chen; Jing Zhang; Haiyan Jia; Jia Li; Huailin Wang; Jihong Wen
Journal:  Mol Med Rep       Date:  2020-11-20       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.